During the First Quarter of the Year, Grupo Nutresa Reported Revenues of More Than COP 4.9 Trillion, an Increase of 13.1%. In Terms of Profitability, the Company Reported a 15.0% EBITDA Margin, the Highest in Over Five Years.
Read More
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials
Mipletamig triplet combination continues to outperform standard doublet benchmark
No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML
Cohort 2 enrollment is complete, and Cohort 3 is now enrolling
Read MoreAntimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis
Read MoreQ1 Revenue of $4.2 Million Driven by OAS Growth and Global Demand for Autonomous Drone Systems
Over 500% Year-over-Year Revenue Growth Reflects Execution on Backlog that has Increased to $16.8 M Driven by Strong Order Momentum; Reaffirms Outlook for at least $25 Million in Revenue for 2025
Ended First Quarter with Over $25 Million of Cash to Support Growth Plan
New Orders Across Europe, the Middle East and the United States Position OAS for Global Expansion in 2025
dot16 Wireless Platform Gains Traction with AAR Selection for NGHE Rail Communications Upgrade; Ondas Networks Now Positioned to Convert this Market Validation into Commercial Adoption
Conference Call Scheduled for Today at 8:30 a.m. ET
Read More
Duane Boise MMJ CEO stated "At the center of the MMJ cannabis pharmaceutical litigation sits DEA Thomas Prevoznik, an unearthed official with no medical or scientific expertise, who wields unchecked power to deny therapies under the guise of public safety."
Read MoreQ1 2025 Results and Subsequent Events
Total net assets of $25.5 million as at Q1 2025, including $26.5 million in non-dilutive funding received in Q1 2025 between sale and leaseback and government programs.
Sale and leaseback transaction closes and generates net proceeds of $13.7 million, plus a $2.0 million deferred payment via vendor loan receivable.
$0.3 million received subsequent to Q1 2025 from NGen.
AGM on May 23, 2025 followed by corporate presentation and Q&A. Reminder to vote by May 21, 2025.
Résultats du T1 2025 et événements ultérieurs
Actif net total de 25,5 M$ au T1 2025, y compris 26,5 M$ en financement non dilutif reçu au T1 2025 de la vente et reprise en location et des programmes gouvernementaux.
La transaction de vente et de reprise en location est conclue et génère un produit net de 13,7 M$, plus un paiement différé de 2,0 M$ via un prêt au vendeur.
0,3 M$ reçus de NGen après le T1 2025.
AGA du 23 mai 2025 suivie d'une présentation de l'entreprise et d'une période de questions. Rappel de voter d'ici le 21 mai 2025.
Highlights for the Quarter ended March 31, 2025:
Management and advisory fee revenue of $18.9 million for the quarter ended March 31, 2025, an increase of 58% over the first quarter of 2024
Net income attributable to Horizon Kinetics Holding Corporation of $22.8 million, or $1.23 per common share for the three months ended March 31, 2025
Assets under management (“AUM”) grew to $10.8 billion as of March 31, 2025, an increase of 54% from March 31, 2024 and 10% from December 31, 2024
Board of Directors declares a $0.056 per share dividend
$5.5 Million Revenue for First Quarter 2025; Cash Balance of $9.7 Million at March 31, 2025
Read More
Revenue increased 40% y/y to $15.0M with Positive Adjusted EBITDA1 for Eighth Consecutive Quarter
Adjusted EBITDA1 of $2.0M or 13% of revenue
Net Profit for the quarter of $0.8M and EPS of $0.02
Reaffirms Fiscal 2025 Revenue Guidance Exceeding $60M, Driven by Strong Order Pipeline
Read More
